Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Climb Bio ( (CLYM) ) has issued an update.
On December 11, 2025, Climb Bio, Inc. entered into an exchange agreement with RA Capital Management and its affiliate, wherein 20,440,000 shares of Climb Bio’s common stock were exchanged for a pre-funded warrant to purchase an equivalent number of shares. This transaction, which is exempt from registration under the Securities Act, will result in RA Capital and its affiliates holding approximately 23% of the company’s voting power. The agreement includes provisions to prevent RA Capital from exceeding 33% ownership of the company’s stock, ensuring a balanced voting power among shareholders.
The most recent analyst rating on (CLYM) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Climb Bio stock, see the CLYM Stock Forecast page.
Spark’s Take on CLYM Stock
According to Spark, TipRanks’ AI Analyst, CLYM is a Neutral.
Climb Bio’s stock score is primarily driven by its financial performance, reflecting the company’s developmental challenges with negative income and cash flow. Despite strong equity and cash reserves, the technical indicators show a bearish trend, and the valuation reflects typical early-stage biotech characteristics with a negative P/E ratio. The absence of significant earnings call data or corporate events means the focus remains on financial stability and potential for future growth.
To see Spark’s full report on CLYM stock, click here.
More about Climb Bio
Average Trading Volume: 608,465
Technical Sentiment Signal: Sell
Current Market Cap: $129.6M
For an in-depth examination of CLYM stock, go to TipRanks’ Overview page.